
According to findings from a retrospective analysis published in JAMA Oncology, the testosterone-related genetic variant HSD3B1 (1245C) is associated with more aggressive disease in patients with metastatic prostate cancer. This is the first clinical trial to validate the relationship between the variant and clinical outcomes, and the results may help physicians determine which patients are more likely to benefit from more aggressive therapy.






